3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
11
Thyroid Carcinoma, Anaplastic
9
Thyroid Cancer, Papillary
4
Neoplasms
3
Multiple Myeloma
3
Glioma
3
Ovarian Neoplasms
2
Melanoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma, Follicular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Stomach Neoplasms
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Nonseminomatous germ cell tumor
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lung Neoplasms
1
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
dabrafenib
×
Head & Neck
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled